down arrow

Chromocell Therapeutics Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1711261057
USD
22.67
0.32 (1.43%)

Dec 18

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

22.0322.67

52 Week

0.5652.82
Valuation
Technical
Day's Volume

CASH

2.81 k

Shareholding (Sep 2024)

FII

0.00%

Held by 0 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

How big is Chromocell Therapeutics Corp.?

22-Jun-2025

As of Jun 18, Chromocell Therapeutics Corp. has a market capitalization of 7.52 million, with net sales of 0.00 million and a net profit of -10.06 million over the latest four quarters. Shareholder's funds are at -6.44 million, and total assets are 0.10 million as of Dec 23.

As of Jun 18, Chromocell Therapeutics Corp. has a market capitalization of 7.52 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -10.06 million.<BR><BR>As of Dec 23, the reporting period shows Shareholder's Funds at -6.44 million and Total Assets at 0.10 million.

Read More

What does Chromocell Therapeutics Corp. do?

22-Jun-2025

Chromocell Therapeutics Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $7.52 million. Key financial metrics indicate it is not profitable, with a P/E ratio and dividend yield of 0.00%.

Overview: <BR>Chromocell Therapeutics Corp. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -2 Million (Quarterly Results - Sep 2024) <BR>Market Cap: USD 7.52 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.72 <BR>Return on Equity: -999,999.00% <BR>Price to Book: -5.27<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Chromocell Therapeutics Corp. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, Chromocell Therapeutics Corp. shows a mildly bullish technical trend, supported by a bullish MACD and moving averages, despite bearish RSI signals, and has significantly outperformed the S&P 500 with a year-to-date return of 5096.57%.

As of 1 August 2025, the technical trend for Chromocell Therapeutics Corp. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the RSI shows bearish signals for both weekly and monthly periods. The daily moving averages are bullish, and the Bollinger Bands indicate a bullish stance on the weekly chart, with a sideways trend on the monthly. Dow Theory reflects a mildly bullish sentiment weekly but mildly bearish monthly. Overall, the technical stance is mildly bullish, driven by the bullish MACD and moving averages, despite the bearish RSI.<BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 5096.57% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 69 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.57

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

-16.48

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-31.94%
0%
-31.94%
6 Months
1789.17%
0%
1789.17%
1 Year
3742.37%
0%
3742.37%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Chromocell Therapeutics Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-1.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.27%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-4.81
EV to EBIT
-1.15
EV to EBITDA
-1.15
EV to Capital Employed
-7.90
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -88.89% vs -80.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.20",
          "val2": "-1.80",
          "chgp": "-77.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.40",
          "val2": "-1.80",
          "chgp": "-88.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -196.00% vs -316.67% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.90",
          "val2": "-2.30",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.10",
          "chgp": "400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.40",
          "val2": "-2.50",
          "chgp": "-196.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.20
-1.80
-77.78%
Interest
0.20
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.40
-1.80
-88.89%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -88.89% vs -80.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.90
-2.30
-200.00%
Interest
0.50
0.10
400.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.40
-2.50
-196.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -196.00% vs -316.67% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Chromocell Therapeutics Corp. stock-summary
stock-summary
Chromocell Therapeutics Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."